Fenofibrate
- Generic Name
- Fenofibrate
- Brand Names
- Antara, Cholib, Fenoglide, Fenomax, Lipidil Supra, Lipofen, Tricor, Triglide
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21ClO4
- CAS Number
- 49562-28-9
- Unique Ingredient Identifier
- U202363UOS
- Background
Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.
Fenofibrate was granted FDA approval on 31 December 1993.
- Indication
Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.
- Associated Conditions
- Mixed Dyslipidemias, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Severe Fredrickson Type IV Hypertriglyceridemia, Severe Fredrickson Type V Hypertriglyceridemia
- Associated Therapies
- -
Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study
- Conditions
- Interventions
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2008-08-13
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT00362765
- Locations
- 🇮🇪
Site 3, Dublin, Ireland
🇫🇮Site 2, Turku, Finland
🇮🇹Site 1, Pisa, Italy
Substrate Cycling in Energy Metabolism
- Conditions
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2010-02-15
- Target Recruit Count
- 40
- Registration Number
- NCT00361751
- Locations
- 🇺🇸
Shriners Hospital for CHildren, Galveston, Texas, United States
Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents
- Conditions
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT00359281
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 101
- Registration Number
- NCT00357500
- Locations
- 🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
- Conditions
- First Posted Date
- 2006-03-21
- Last Posted Date
- 2006-03-21
- Lead Sponsor
- Foundation Research, Florida
- Target Recruit Count
- 30
- Registration Number
- NCT00304993
- Locations
- 🇺🇸
Foundation Research, St. Petersburg, Florida, United States
Obesity and Nonalcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 51
- Registration Number
- NCT00262964
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate
- Conditions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00261352
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Insulin Resistance in Non-alcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 13
- Registration Number
- NCT00252499
- Locations
- 🇺🇸
VA Puget Sound Health Care System, Seattle, Seattle, Washington, United States
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 221
- Registration Number
- NCT00246376
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-10-04
- Lead Sponsor
- Abbott
- Target Recruit Count
- 174
- Registration Number
- NCT00195793
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.